MedTrace Logo

A Pharmacokinetic Study: Ranibizumab, Aflibercept and the Effect of Vitrectomy.

NCT02174211 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2021-04-30

No results posted yet for this study

Summary

To study the effect of pars plana vitrectomy on the intravitreal pharmacokinetics of ranibizumab and to compare the half-life of ranibizumab and aflibercept.

Conditions

  • Age Related Macular Degeneration

Interventions

DRUG

Ranibizumab

Intravitreal injection of ranibizumab

DRUG

Aflibercept

Intravitreal injection of aflibercept

Sponsors & Collaborators

Principal Investigators

  • Timothy L Jackson, PhD,FRCOphth · King's College Hospital NHS Trust

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2020-11-30
Completion
2020-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02174211 on ClinicalTrials.gov